scholarly journals Quadrivalent Human Papillomavirus Vaccine and the Young Ovary: Review of Safety Research Following Two Case Series of Premature Ovarian Insufficiency

2017 ◽  
Author(s):  
Little D
Keyword(s):  
Human Papillomavirus ◽  
Case Series ◽  
Premature Ovarian Insufficiency ◽  
Human Papillomavirus Vaccine ◽  
Ovarian Insufficiency ◽  
Safety Research ◽  
Papillomavirus Vaccine

Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance

Sexual Health ◽  
2010 ◽  
Vol 7 (3) ◽  
pp. 320 ◽  
Author(s):  
Michael S. Gold ◽  
Jim Buttery ◽  
Peter McIntyre
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Case Series ◽  
Vaccine Safety ◽  
Age Group ◽  
Human Papillomavirus Vaccine ◽  
Federally Funded ◽  
Conversion Disorders ◽  
Passive Surveillance System ◽  
Papillomavirus Vaccine

Australia was one of the first countries to licence a quadrivalent human papillomavirus (HPV) vaccine, rapidly followed by a federally funded program of universal vaccination of a broad age group of females through schools (12 to 18 years) and primary care (19 to 26 years). As of August 2009, more than 5.8 million doses of Gardasil® (quadrivalent; Merck, New Jersey, USA) have been distributed in Australia and a total of 1394 suspected adverse events following immunisation (AEFI) have been reported to the passive surveillance system. Most reports are of common and expected reactions. Case series of more uncommon and serious AEFI, both known to be potentially vaccine related (anaphylaxis, conversion disorders and lipoatrophy) and otherwise (multiple sclerosis and pancreatitis) have been published.

Vaccine Hesitancy and Differential Susceptibility to Media Coverage: A Critical Documentary Led to Substantial Reductions in Human Papillomavirus Vaccine Uptake in Denmark

2021 ◽  
pp. 0272989X2110035
Author(s):  
Maria Knoth Humlum ◽  
Niels Skipper ◽  
Peter Rønø Thingholm
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Media Coverage ◽  
Differential Susceptibility ◽  
Vaccine Uptake ◽  
Vaccine Hesitancy ◽  
Human Papillomavirus Vaccine ◽  
Policy Makers ◽  
Quasi Experimental ◽  
Papillomavirus Vaccine

Objectives To investigate whether negative media coverage of the human papillomavirus (HPV) vaccine led to a decrease in the uptake of the first dose of the HPV vaccine (HPV1) in Denmark and, importantly, whether some groups of individuals were more susceptible to negative media coverage. Methods We measured HPV vaccine uptake of 12-year-old girls born in 2001 to 2004 using Danish administrative data. A quasi-experimental design was employed to assess whether a documentary that was critical of the HPV vaccine and aired in March 2015 affected HPV uptake. Results The documentary led to a quick and substantial decrease in the monthly propensity to vaccinate, which dropped 3 percentage points—or about 50%—in response to the documentary. Responses differed substantially across subgroups, and girls from families with high socioeconomic status (SES) were more susceptible to the negative media coverage. Conclusions Susceptibility to negative media coverage varied substantially across subgroups, highlighting the need for policy makers to appropriately target and differentiate initiatives to improve vaccine compliance rates.

Human Papillomavirus Vaccine-Induced Cytokine Messenger RNA Expression in Vaccinated Women

2015 ◽  
Vol 28 (6) ◽  
pp. 339-342 ◽  
Author(s):  
Ana Katherine Gonçalves ◽  
Paulo César Giraldo ◽  
Paula Renata Lima Machado ◽  
Kleber Juvenal Silva Farias ◽  
Ana Paula Ferreira Costa ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Messenger Rna ◽  
Rna Expression ◽  
Human Papillomavirus Vaccine ◽  
Papillomavirus Vaccine
Sign in / Sign up

Export Citation Format

Share Document